This webpage is intended for UK healthcare professionals. If you are not a healthcare professional, please click here.

Introducing the NEW button-free Metoject® PEN

Offering the simplicity of a button-free autoinjector, purpose designed with patient-friendly features – Available from March 2024

Learn more about the new Metoject® PEN

Metoject® PEN Training & Support

Metoject® PEN is a once a week pre-filled methotrexate auto-injector, indicated for treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, psoriasis and Crohn’s disease1.

Administering Metoject® PEN

The following video explains the Metoject® PEN self-injection process.

Patients must be educated and trained in the proper injection technique when self-administering methotrexate.

Metoject® PEN should only be administered once a week

Metoject® PEN Contraindications

Metoject® PEN is contraindicated in the case of1:

  • Hypersensitivity to the active substance or to any of the excipients
  • Severe liver impairment
  • Alcohol abuse
  • Severe renal impairment (creatinine clearance less than 30 ml/min)
  • Pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anaemia
  • Serious, acute or chronic infections such as tuberculosis, HIV or other immunodeficiency syndromes
  • Ulcers of the oral cavity and known active gastrointestinal ulcer disease
  • Pregnancy, breast-feeding
  • Concurrent vaccination with live vaccines

Training & Support Materials

Usage for Adults
Usage for Children

Further Support

Please use the following buttons to download Metoject® PEN SPC, ordering information, and prescribing information.

Metoject®
PEN SPC Ordering
Metoject® PEN Metoject® PEN
Prescribing Information
Metoject®
PEN SPC Ordering
Metoject® PEN Metoject® PEN
Prescribing Information

Treatment Categories

Please select the relevant link below for Metoject® PEN usage information for dermatology or rheumatology.

Dermatology Rheumatology

Reporting Side Effects

Adverse events should be reported using the forms and information found at yellowcard.mhra.gov.uk

Please also report any adverse events by email to medac drug safety at drugsafety@medac.de

Further Information & Questions

Visit our contact page to submit an enquiry

References:

  1. Metoject® Summary of Product Characteristics. [online] Available at: https://www.medicines.org.uk/emc/search?q=metoject#gref/. Last Accessed May 2023
  2. Müller, R.B. et al. (2015). Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Seminars in Arthritis and Rheumatism, 45(1), pp.28–34.
  3. Pichlmeier, U., & Heuer, K. U. (2014). Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clinical and experimental rheumatology, 32(4), 563–571.
  4. Kromann, C.B. et al. (2014). Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? Journal of Dermatological Treatment, 26(2), pp.188–190.
  5. EU Council Directive 2010/32/EU on the prevention of sharps injuries in the hospital and healthcare sector
  6. Latex data on file
  7. Braun, J. et al. (2008). Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis and rheumatism, 58(1), 73–81.
  8. Methotrexate and its use in rheumatoid arthritis (RA). [online] Available at: https://nras.org.uk/resource/methotrexate/. Last Accessed May 2023.
  9. Johnson, T.M. et al. (2021). Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Annals of the Rheumatic Diseases, [online] 80(11), pp.1385–1392.
  10. O’Connor, A. et al. (2016). The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study. BMC Musculoskeletal Disorders, 17(1).
  11. Kanwar, A., Yadav, S. and Dogra, S. (2010). Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics? Indian Journal of Dermatology, Venereology, and Leprology, 76(6), p.622.
  12. Warren, R.B. et al. (2017). An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10068), pp.528–537.
  13. Reich, K. et al. (2020). The value of subcutaneous vs. oral methotrexate: real‐world data from the German psoriasis registry PsoBest. British Journal of Dermatology, 184(4), pp.765–767.
  14. Generali, E. et al. (2021). Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis. Journal of Translational Autoimmunity, 4, p.100113.

Contact Us

For more information, please contact medac Pharma:

Tel: +44 (0)1786 458086
Email: info@medacpharma.co.uk
Web: medacpharma.co.uk

medac Pharma LLP
Scion House
Stirling University Innovation Park
Stirling
FK9 4NF

Terms & Conditions
Privacy Policy
Cookies Policy
medac Pharma website
Copyright © medac Pharma LLP 2024

medacuk015/03/2023
March 2023